7 gennaio 2008 / 14:29 / tra 10 anni

Osiris ends agreement with Boston Scientific

Jan 7 (Reuters) - Osiris Therapeutics Inc OSIR.O said it ended a development and selling agreement with Boston Scientific Corp (BSX.N) for Prochymal as it looks to enter territory-specific, rather than indication-specific deals for the drug.

Osiris said it reclaimed sole worldwide rights to cardiovascular indications for Prochymal, an adult stem-cell therapy.

Osiris said it will relieve the drug giant of a $50 million loan obligation and $45 million in development payments. Osiris said it will also repay a $5 million debt, and accrued interest, in four quarterly installments. (Reporting by Varsha Tickoo in Bangalore)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below